Mendelian randomization study of GLP-1R effects on ovarian cancer subtypes mediated by metabolic factors
The protective effect of GLP-1R agonists on ovarian cancer, especially ENOC, needs further validation in large-scale and well-conducted clinical trials.
Authors
- Qiuhong Gong (ORCID: https://orcid.org/0000-0002-8781-1214)
- Yuhong Chen (ORCID: https://orcid.org/0000-0002-4396-6353)
- Jieli Lu
- Yufang Bi
- Limin Wang
- Qian Yang
- Shuangyuan Wang
- Min Xu
- Hong Lin
- Yu Xu
- Mian Li
- Zhihe Chen
- Jie Zheng
- Tiange Wang
- Zhiyun Zhao
- Guang Ning
Institutions
- Shanghai Jiao Tong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Ruijin Hospital (CN)
- University of Bristol (GB)
- National Center for Chronic and Noncommunicable Disease Control and Prevention (CN)
- MRC Epidemiology Unit (GB)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1038/s43856-026-01379-y
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Shanghai Municipal Education Commission
- National Science and Technology Major Project
- National Key Research and Development Program of China